Kleijnen Systematic Reviews Ltd, York, UK.
KSR Evidence Ltd, York, UK.
Syst Rev. 2024 May 8;13(1):126. doi: 10.1186/s13643-024-02552-x.
The unprecedented volume and speed at which COVID-19-related systematic reviews (SRs) may have been produced has raised questions regarding the quality of this evidence. It is feasible that pandemic-related factors may have led to an impairment in quality (reduced internal validity, increased risk of bias [RoB]). This may have serious implications for decision-making related to public health and individual healthcare.
The primary objective was to compare the quality of SRs published during the pandemic that were related to COVID-19 with SRs published during the pandemic that were unrelated to COVID-19 (all of which were fully appraised in the KSR Evidence database of SRs in healthcare). Our secondary objective was to compare the quality of SRs published during the pandemic (regardless of research topic), with SRs published pre-pandemic.
We compared all SRs related to COVID-19 to all SRs unrelated to COVID-19 that (i) were published during the pandemic (between 1st March 2020 and September 14, 2022), (ii) were included in KSR Evidence, and (iii) had been appraised using the ROBIS tool. We then compared all SRs published during the pandemic (regardless of research topic) with a pre-pandemic sample of SRs.
For SRs published during the pandemic, we found there was no statistically significant difference in quality between those SRs tagged as being related to COVID-19 and those that were not [relative risk (RR) of low RoB for COVID-19 versus COVID-19-unrelated reviews: 0.94; 95% confidence interval (CI): 0.66 to 1.34]. Generally, COVID-19 SRs and COVID-19-unrelated SRs were both of low quality with only 10% of COVID-19 reviews and 11% of COVID-19-unrelated reviews rated as low RoB. However, SRs (regardless of topic) published during the pandemic were of lower quality than those published pre-pandemic (RR for low RoB for 'during pandemic' versus 'pre-pandemic': 0.30; 95% CI: 0.26 to 0.34) with 11% of pandemic and 36% of pre-pandemic SRs rated as low RoB.
These results suggest COVID-19 and COVID-19-unrelated SRs published during the pandemic are equally of low quality. SRs published during the pandemic were generally lower quality compared with SRs published pre-pandemic irrespective of COVID-19 focus. Moreover, SR quality in general is seriously lacking, and considerable efforts need to be made to substantially improve the quality and rigour of the SR process.
与 COVID-19 相关的系统评价(SR)的数量和速度空前,这引发了对这些证据质量的质疑。大流行相关因素可能导致质量受损(内部有效性降低,偏倚风险增加[RoB])是有可能的。这可能对与公共卫生和个人医疗保健相关的决策产生严重影响。
主要目的是比较大流行期间发表的与 COVID-19 相关的 SR 与大流行期间发表的与 COVID-19 无关的 SR 的质量(所有这些 SR 都在 KSR Evidence 医疗保健中的 SR 证据数据库中进行了全面评估)。我们的次要目标是比较大流行期间发表的 SR 的质量(无论研究主题如何)与大流行前发表的 SR 的质量。
我们将所有与 COVID-19 相关的 SR 与所有与 COVID-19 无关的 SR 进行了比较(i)在大流行期间发表(2020 年 3 月 1 日至 2022 年 9 月 14 日),(ii)收录在 KSR Evidence 中,(iii)使用 ROBIS 工具进行评估。然后,我们将大流行期间发表的所有 SR(无论研究主题如何)与大流行前的 SR 样本进行了比较。
对于大流行期间发表的 SR,我们发现与 COVID-19 相关的 SR 与不相关的 SR 之间的质量没有统计学上的显著差异[COVID-19 与 COVID-19 无关的低 RoB 比值比(RR):0.94;95%置信区间(CI):0.66 至 1.34]。一般来说,COVID-19 的 SR 和 COVID-19 无关的 SR 质量都较低,只有 10%的 COVID-19 审查和 11%的 COVID-19 无关的审查被评为低 RoB。然而,大流行期间发表的 SR(无论主题如何)的质量都低于大流行前发表的 SR(低 RoB 的“大流行期间”与“大流行前”的 RR:0.30;95%CI:0.26 至 0.34),11%的大流行期间和 36%的大流行前的 SR 被评为低 RoB。
这些结果表明,大流行期间发表的 COVID-19 相关和不相关的 SR 质量同样较低。大流行期间发表的 SR 一般质量低于大流行前发表的 SR,无论 COVID-19 重点如何。此外,SR 的质量普遍严重不足,需要做出相当大的努力来大大提高 SR 过程的质量和严谨性。